Skip to main content

Table 1 Antibodies and scoring system used for analysis

From: COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ

Antibody*

Dilution

Clone

Method of scoring

ER-α

1:300

1D5

> 10% positive cells – positive, < 10%- negative

PR

1:400

PgR636

> 10% positive cells – positive, < 10%- negative

HER-2/neu

1:200

**

Scored as +1, +2 and +3, +3- positive, +1/+2 -negative

COX-2

1:100

CX229

Strong positive, weak positive, negative

PPARγ

1:50

E8

Nuclear, cytoplasmic, nuclear+cytoplasmic, negative

P53

1:200

DO-7

> 10% positive cells – positive, < 10% -negative

P21

1:50

SX118

> 10% positive cells – positive, < 10% -negative

Cyclin D1

1:300

DCS-6

> 10% positive cells – positive, < 10% -negative

  1. *All antibodies were purchased from Dako Cytomation except COX-2 (Cayman Chemicals), PPARγ (Santa Cruz Biotechnologies), Cyclin E (Lab Vision Corporation) and CXCR4 (R&D Systems)
  2. ** DAKO polyclonal antibody A0485.